Indication intelligence, analysis and sector perception

Cellectis S.A. (ARD: CLLS) T-Cells tied to remission of Leukemia in patient and is UP +$3.84 or +10.07% in pre-market - BUY

November 5, 2015 9:31am

Infusion of Cellectis’s UCART19 T-cells helped induce molecular remission in 11-month-old with acute lymphoblastic leukemia after all other treatments failed, according to investigator-sponsored data being presented at American Society of Hematology annual meeting.

Patient received single dose without significant toxicity

UCART19 T cells were detectable by qPCR in circulation by day 14, and at increased levels in both blood and marrow on day 28

The Boittom Line: Patient showed signs of count recovery and bone marrow, while hypoplastic, was in cytogenetic and molecular remission. U.K. researchers said first-in-human use provides early proof-of-concept for off-the-shelf CAR T-cell approach

CLLS closed DOWN -$3.57 to $35.01 and is UP +$3.84 or +10.07% in pre-market

< Source: Bloomberg by Catherine Larkin and Caroline Chen>

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

8 hours 37 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.